NCT02761174 is a Phase 4 clinical trial of Brimonidine in Telangiectasias, sponsored by Merete Haedersdal.

Who is sponsoring NCT02761174?

NCT02761174 is sponsored by Merete Haedersdal.

What drugs are being tested in NCT02761174?

Interventions in NCT02761174: Brimonidine, IPL+air-cooling.

What condition does NCT02761174 study?

NCT02761174 studies Telangiectasias.

Is NCT02761174 still recruiting?

NCT02761174 is currently completed. Last updated 5 January 2018.

Last reviewed 2018-01-05 · How we verify

NCT02761174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

Completed Phase 4 Last updated 5 January 2018

What this trial tests

Phase 4 trial testing Brimonidine in Telangiectasias in 19 participants. Completed in 13 January 2017.

Timeline

13 March 2016

Primary endpoint
11 July 2016

13 January 2017

Quick facts

Lead sponsor	Merete Haedersdal
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	19
Start date	13 March 2016
Primary completion	11 July 2016
Estimated completion	13 January 2017
Sites	1 location across Denmark

Drugs / interventions tested

Brimonidine (BRIMONIDINE) — full drug profile →
IPL+air-cooling

Conditions studied

Telangiectasias — all drugs for Telangiectasias →

Sponsor

Merete Haedersdal — full company profile →

Who can join

Adults 18 to 65, any sex, with Telangiectasias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate whether brimonidine cream can reduce IPL-induced inflammation in terms of redness, swelling and pain in patients with facial vascular lesions (telangiectasias). Furthermore, the effect of brimonidine cream on IPL-efficacy is evaluated one month after final IPL-treatment. The hypothesis is that brimonidine, which has been proved effective in reduction of symptomatic erythema in patients with rosacea, also may have the ability to reduce IPL-induced erythema. Since the potential reduction in erythema is caused by vasoconstriction, brimonidine may further reduce IPL-induced oedema and pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of adrenergic receptor signalling in neuroimmune communication.
Chhatar S, Lal G. · · 2021 · cited 76× · PMID 35492402 · DOI 10.1016/j.crimmu.2021.11.001

Verify or expand the search:

Other trials of Brimonidine

Trials testing the same drug.

NCT06449352 — Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost · Phase 4 · completed
NCT05656027 — Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia · Phase 3 · completed
NCT03959176 — The Effect of Brimonidine · Phase 4 · completed
NCT03418727 — Dry Eye Disease Study With Brimonidine · Phase 2 · completed
NCT01144494 — Aqueous Humor Dynamics and Brimonidine · EARLY_PHASE1 · completed

Other Merete Haedersdal trials

Trials by the same sponsor.

NCT05937529 — Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis · NA · completed
NCT05461755 — Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin · Phase 2 · completed
NCT05202860 — Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis · Phase 2 · active not recruiting
NCT05057117 — Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis · Phase 4 · completed
NCT04221126 — TMFI Enhances Skin Surface and Epidermal PpIX Fluorescence · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02761174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merete Haedersdal
Last refreshed: 5 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02761174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing